Minna Harmanen
YOU?
Author Swipe
View article: Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression‐Free Survival in Diffuse Large B‐Cell Lymphoma
Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression‐Free Survival in Diffuse Large B‐Cell Lymphoma Open
Introduction Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease, with often a high Ki‐67 proliferation index. Prognosis is associated with lymphoma stage, lactate dehydrogenase level, and metabolic tumor volume. Thus, intuiti…
View article: Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria
Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria Open
Mantle cell lymphoma (MCL) is a rare and heterogeneous subgroup of B-cell lymphomas. The clinical course of MCL varies from an indolent form to an extremely aggressive phenotype. MCL is still an incurable disease. However, intensified chem…
View article: LIFETIME TREATMENT BURDEN OF PATIENTS WITH MANTLE CELL LYMPHOMA: SIMULATION‐BASED ANALYSIS OF REAL‐WORLD DATA FROM 20 YEARS
LIFETIME TREATMENT BURDEN OF PATIENTS WITH MANTLE CELL LYMPHOMA: SIMULATION‐BASED ANALYSIS OF REAL‐WORLD DATA FROM 20 YEARS Open
Background: Mantle cell lymphoma (MCL) is a rare subtype of B-cell lymphoma that is currently considered incurable, yet treatable condition with increasing amount of treatment options. Alas, the availability of novel therapies is often lim…
View article: CD34+ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients
CD34+ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients Open
Backgound: Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy. Study Design and Methods: This prospective multicenter study eva…
View article: Supplementary Material for: CD34+ CELL MOBILIZATION, AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MANTLE CELL LYMPHOMA PATIENTS
Supplementary Material for: CD34+ CELL MOBILIZATION, AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MANTLE CELL LYMPHOMA PATIENTS Open
BACKGOUND: Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy. STUDY DESIGN AND METHODS: This prospective multicenter study eva…
View article: Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020 Open
Summary Mantle cell lymphoma (MCL) is a rare peripheral B‐cell lymphoma characterised by eventual relapse and progression towards a more aggressive disease biology. With the introduction of rituximab‐ and cytarabine‐based immunochemotherap…
View article: Risk factors of venous thromboembolic events among diffuse large B-cell lymphoma patients receiving first-line treatment
Risk factors of venous thromboembolic events among diffuse large B-cell lymphoma patients receiving first-line treatment Open
Venous thromboembolic events (VTEs) remain a major cause of mortality and morbidity among lymphoma patients. In this retrospective study, we analyzed the risk factors for VTEs in DLBCL (diffuse large B-cell lymphoma) patients treated with …
View article: Risk factors of venous thromboembolic events among diffuse large B-cell lymphoma patients receiving first-line treatment
Risk factors of venous thromboembolic events among diffuse large B-cell lymphoma patients receiving first-line treatment Open
Background Venous thromboembolic events (VTEs) remain a major cause of mortality and morbidity among lymphoma patients. Accurate risk-prediction models are lacking, however, especially in the high VTE risk subgroup of diffuse large B-cell …